Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

被引:174
作者
Moghaddam, Samar Masoumi [1 ]
Amini, Afshin [1 ]
Morris, David L.
Pourgholami, Mohammad H. [1 ]
机构
[1] Univ New S Wales, Canc Res Labs, Dept Surg, St George Hosp, Sydney, NSW 2217, Australia
关键词
Angiogenesis; Bevacizumab; Malignant ascites; Ovarian cancer; Peritoneal carcinomatosis; Vascular endothelial growth factor; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; PHASE-II TRIAL; PLATINUM-BASED CHEMOTHERAPY; SERUM VEGF LEVELS; PERMEABILITY FACTOR; EPITHELIAL OVARIAN; TUMOR-GROWTH; MALIGNANT ASCITES; FACTOR EXPRESSION; CARCINOMA CELLS;
D O I
10.1007/s10555-011-9337-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis which drives endothelial cell survival, proliferation, and migration while increasing vascular permeability. Playing an important role in the physiology of normal ovaries, VEGF has also been implicated in the pathogenesis of ovarian cancer. Essentially by promoting tumor angiogenesis and enhancing vascular permeability, VEGF contributes to the development of peritoneal carcinomatosis associated with malignant ascites formation, the characteristic feature of advanced ovarian cancer at diagnosis. In both experimental and clinical studies, VEGF levels have been inversely correlated with survival. Moreover, VEGF inhibition has been shown to inhibit tumor growth and ascites production and to suppress tumor invasion and metastasis. These findings have laid the basis for the clinical evaluation of agents targeting VEGF signaling pathway in patients with ovarian cancer. In this review, we will focus on VEGF involvement in the pathophysiology of ovarian cancer and its contribution to the disease progression and dissemination.
引用
收藏
页码:143 / 162
页数:20
相关论文
共 259 条
[1]  
AbuJawdeh GM, 1996, LAB INVEST, V74, P1105
[2]  
Aghajanian C., 2011, ASCO M S, V29
[3]   Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: An exception to the norm [J].
Ahmed, Nuzhat ;
Thompson, Erik W. ;
Quinn, Michael A. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2007, 213 (03) :581-588
[4]   Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study [J].
Akahira, JI ;
Yoshikawa, H ;
Shimizu, Y ;
Tsunematsu, R ;
Hirakawa, T ;
Kuramoto, H ;
Shiromizu, K ;
Kuzuya, K ;
Kamura, T ;
Kikuchi, Y ;
Kodama, S ;
Yamamoto, K ;
Sato, S .
GYNECOLOGIC ONCOLOGY, 2001, 81 (03) :398-403
[5]   Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2 [J].
Annunziata, Christina M. ;
Walker, Amanda J. ;
Minasian, Lori ;
Yu, Minshu ;
Kotz, Herbert ;
Wood, Bradford J. ;
Calvo, Katherine ;
Choyke, Peter ;
Kimm, Daniel ;
Steinberg, Seth M. ;
Kohn, Elise C. .
CLINICAL CANCER RESEARCH, 2010, 16 (02) :664-672
[6]  
[Anonymous], 2003, Clin Colorectal Cancer, V3, P16
[7]  
[Anonymous], 2009, J CLIN ONCOL
[8]  
[Anonymous], ASCO M S
[9]  
[Anonymous], J CLIN ONCOL S
[10]   Pattern and prognostic factors in patients with malignant ascites: a retrospective study [J].
Ayantunde, A. A. ;
Parsons, S. L. .
ANNALS OF ONCOLOGY, 2007, 18 (05) :945-949